Sjögren's syndrome medical therapy: Difference between revisions
Jump to navigation
Jump to search
Farima Kahe (talk | contribs) |
Farima Kahe (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Sjögren's syndrome}} | {{Sjögren's syndrome}} | ||
{{CMG}} | {{CMG}} {{AE}} {{F.K}} | ||
==Overview== | ==Overview== | ||
Revision as of 20:20, 2 April 2018
|
Sjögren's syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Sjögren's syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Sjögren's syndrome medical therapy |
|
Risk calculators and risk factors for Sjögren's syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Farima Kahe M.D. [2]
Overview
Medical Therapy
- Dry eye, dry mouth, and other sicca symptoms:
- Preferred regimen (1): Pilocarpine 5 mg PO q8h
- Preferred regimen (2): Cevimeline 30 mg PO q8h
- Organ-based disease and constitutional symptoms:
- Preferred regimen (1): Hydroxychloroquine 5 mg PO q8h
- Preferred regimen (2): Methotrexate 30 mg PO q8h
- Preferred regimen (2): Leflunomide 30 mg PO q8h
- Preferred regimen (2): Azathioprine 30 mg PO q8h
- Preferred regimen (2): Sulfasalazine 30 mg PO q8h
- Preferred regimen (2): Cyclosporine 30 mg PO q8h
- Preferred regimen (2): Cyclophosphamide 30 mg PO q8h
- Preferred regimen (2): Rituximab 30 mg PO q8h